Progeny 3, Inc. Regeneron Pharmaceuticals, Inc. Transaction History
Progeny 3, Inc.
- $1.19 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding REGN
# of Institutions
1,531Shares Held
84.1MCall Options Held
1.22MPut Options Held
1.51M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.88 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6.23 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.53 Billion0.65% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.62 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$3.17 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $79.1B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...